What happens when you stop Weight-Loss shots? new study tests backup plans

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Previous hx of BMI of \>30 or BMI of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease) * Currently taking Wegovy, Ozempic, Mounjaro or Zepbound and have been for at least 6 months * At least 15% body weight loss since taking Wegovy, Ozempic, Mounjaro, or Zepbound * Willing to stop taking their GLP-1 medication or is discontinuing due to circumstances such as access, cost, coverage, choice, or any other reason * Ability to provide informed consent prior to any trial-related activities * Able to read and write in English Exclusion Criteria: * BMI \<22 kg/m2 * Diabetes * Previous surgical obesity treatment * Currently pregnant or intending to become pregnant during the study * Breastfeeding * History of seizures or epilepsy * Current opioid use or in acute opioid withdrawal * Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs * History of glaucoma * Uncontrolled hypertension * Severe renal impairment and/or Chronic kidney disease stage III or GFR \<60 * Acute hepatitis or liver failure * Acute or chronic metabolic acidosis, including diabetic ketoacidosis * Use of antipsychotic medications or opiod analgesics * Current or previous history of anorexia or bulimia nervosa * Engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight * Current SSRI, SNRI, mood stabilizer, amphetamine, or corticosteroid use * Current diagnosis of hyper or hypothyroidism or current use of thyroid replacement medicine * Current use of beta blockers * Current use of depo shot (medroxyprogesterone acetate) for birth control * Current diagnosis of Cushing's disease or syndrome * Current use of Monoamine Oxidase Inhibitors (MAOIs) * Known hypersensitivity to bupropion, naltrexone, or metformin * Any other reason rendering a participant unsuitable for trial participation, as determined by a clinician or study investigator